title: Engineered T cells for cancer therapy.
abstract: It is now well established that the immune system can control and eliminate cancer cells. Adoptive T cell transfer has the potential to overcome the significant limitations associated with vaccine-based strategies in patients who are often immune compromised. Application of the emerging discipline of synthetic biology to cancer, which combines elements of genetic engineering and molecular biology to create new biological structures with enhanced functionalities, is the subject of this focused research review.
authors.affiliation: Abramson Cancer Center, University of Pennsylvania, 3400 Civic Center Boulevard, 8th Floor, Philadelphia, PA, 19104-5156, USA, cjune@exchange.upenn.edu.
authors.forename: Carl H
authors.initials: CH
authors.lastname: June
authors.forename: Marcela V
authors.initials: MV
authors.lastname: Maus
authors.forename: Gabriela
authors.initials: G
authors.lastname: Plesa
authors.forename: Laura A
authors.initials: LA
authors.lastname: Johnson
authors.forename: Yangbing
authors.initials: Y
authors.lastname: Zhao
authors.forename: Bruce L
authors.initials: BL
authors.lastname: Levine
authors.forename: Stephan A
authors.initials: SA
authors.lastname: Grupp
authors.forename: David L
authors.initials: DL
authors.lastname: Porter
mesh_terms: D000818:Animals; D005818:Genetic Engineering / Q000379:methods; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D011948:Receptors, Antigen, T-Cell / Q000235:genetics; D013601:T-Lymphocytes / Q000276:immunology*
chemical_list: D011948:Receptors, Antigen, T-Cell